Citation: Curcio CA. Soft drusen in age-related macular degeneration: biology and targeting via the Oil Spill strategies. Invest Ophthalmol Vis Sci. 2018;59:AMD160-AMD181. https:// doi.org/10.1167/iovs. AMD is a major cause of legal blindness in older adults approachable through multidisciplinary research involving human tissues and patients. AMD is a vascularmetabolic-inflammatory disease, in which two sets of extracellular deposits, soft drusen/ basal linear deposit (BLinD) and subretinal drusenoid deposit (SDD), confer risk for end-stages of atrophy and neovascularization. Understanding how deposits form can lead to insights for new preventions and therapy. The topographic correspondence of BLinD and SDD with cones and rods, respectively, suggest newly realized exchange pathways among outer retinal cells and across Bruch's membrane and the subretinal space, in service of highly evolved, eyespecific physiology. This review focuses on soft drusen/BLinD, summarizing evidence that a major ultrastructural component is large apolipoprotein B,E-containing, cholesterol-rich lipoproteins secreted by the retinal pigment epithelium (RPE) that offload unneeded lipids of dietary and outer segment origin to create an atherosclerosis-like progression in the subRPEbasal lamina space. Clinical observations and an RPE cell culture system combine to suggest that soft drusen/BLinD form when secretions of functional RPE back up in the subRPE-basal lamina space by impaired egress across aged Bruch's membrane-choriocapillary endothelium. The soft drusen lifecycle includes growth, anterior migration of RPE atop drusen, then collapse, and atrophy. Proof-of-concept studies in humans and animal models suggest that targeting the ''Oil Spill in Bruch's membrane'' offers promise of treating a process in early AMD that underlies progression to both end-stages. A companion article addresses the antecedents of soft drusen within the biology of the macula.
INTRODUCTION AND SYNOPSIS
A MD is a major cause of legal blindness in older adults approachable through multidisciplinary research involving human tissues and patients via clinical imaging and genetics. The central theses of this review are as follows:
1. Soft drusen and basal linear deposit (BLinD) are two forms of the same extracellular lipid rich material that together make up an Oil Spill on Bruch's membrane (BrM). Drusen are defined in reference to a three-layer BrM and in distinction to other entities that are not drusen; 2. AMD is a vascular-metabolic-inflammatory disease in which soft drusen/BLinD and subretinal drusenoid deposit (SDD; also called reticular pseudodrusen) are major risk factors for progression to end-stages of atrophy and neovascularization that involve substantial loss of retinal pigment epithelium (RPE) and photoreceptors 1 ; 3. The topographic relation of soft drusen/BLinD to cones and SDD to rods strongly suggests that deposit biogenesis reflects newly realized exchange pathways among cones, rods, RPE, Müller cells, and choriocapillary endothelium, across BrM and the subretinal space, in service of highly evolved, eye-specific physiology; 4. A major component of soft drusen/BLinD is lipoprotein particles containing apolipoproteins B and E, secreted by RPE in a physiologic lipid-recycling program. The composition suggests a dual origin of lipids (fatty acids from diet, cholesterol from diet and photoreceptor outer segments); 5. Clinical imaging and an RPE cell culture system together define a druse lifecycle to which RPE demise can be linked. Soft drusen/BLinD form when secretions of functional RPE back up in the subRPE-basal lamina space, because egress across aged BrM-choriocapillary endothelium is impaired. Drusen can expand in volume, RPE migrate off the top into the retina, leading to disintegration of the RPE layer, druse collapse, and atrophy; 6. The Oil Spill strategies for druse abatement to forestall type 1 neovascularization and geographic atrophy have supportive preclinical and clinical data; and 7. Understanding outer retinal physiology driving lipoprotein production has potential to advance treatments as impactful for AMD as statins have been for atherosclerotic cardiovascular disease; relevant model systems exist.
hypothesis is limited to discussion of soft drusen (and their differential diagnoses) and should be contextualized among other known contributors to AMD pathobiology. These include aging in the choroidal vasculature, 2 inflammation, and activity of resident/transient immune cells, 3 among others. Many mechanisms operating simultaneously give rise to AMD's complexity. Validated multimodal clinical imaging offers bright prospects for connecting disparate pieces in a coherent timeline to clarify therapeutic strategies. Despite knowledge gaps, enough is known about soft drusen/BLinD biology to launch new approaches. A companion article considers what aspects of macular biology drive soft drusen biogenesis. 4 
NEUROBIOLOGY AND AGING OF THE MACULA
A neurovascular unit 5, 6 comprises microvessels, neurons, glia, pericytes, and extracellular matrix that link blood flow to the metabolic demands of neurons. The cells and tissues most prominently affected by AMD pathology are those of the outer retinal neurovascular unit 7 (i.e., photoreceptors, RPE, Müller cells [in neurosensory retina], and the choriocapillaris [ChC] endothelium [in the choroidal vasculature]). The choroid has the highest blood flow in the body, and the choriocapillaris is sinusoidal and fenestrated. Between RPE and ChC is a laminated subendothelial extracellular matrix called Bruch's membrane (BrM), which functions as a vessel wall laid out flat, paralleling vascular lumens. 8 The RPE is a monolayer of cuboidal polygonal cells embedded between photoreceptors and BrM. Strong apical to basolateral polarization makes the RPE a key player in the homeostasis of photoreceptors and the pathology of SDD apically and choriocapillaris and the pathology of drusen basally. The macular neurosensory retina consists of a 0.8-mm diameter all-cone fovea surrounded by a rod-dominated annulus of 6-mm outer diameter. The Henle fiber layer contains inner fibers of photoreceptors and Müller glia that form junctions at the external limiting membrane. Among numerous Müller cell functions 9 are recently recognized roles in delivering to cones for phototransduction vitamin A derivatives of dietary origin. 10, 11 Xanthophyll pigments lutein and zeaxanthin are prominent in the foveal center, and lutein, in the Henle fiber and inner plexiform layers. 12, 13 A hypothesis that Müller cells are major xanthophyll reservoirs is explored separately. 4 Of major age-related tissues changes detailed separately, 4 we focus on BrM, where AMD pathology is prominent, including cross-linking, 14 thickening, 15 and lipidization, [16] [17] [18] and loss of ChC density and apposition to BrM. 19 The lipidization of BrM provides a straightforward path to lipids in soft drusen, arguably the first druse component described. [20] [21] [22] [23] [24] Lipid accumulation in vessel walls connects to both the pathophysiology of atherosclerotic cardiovascular disease 25 and the clinical success in reducing its public health burden. 26 
DEFINING THE LAYERS OF AMD
A cellular-and molecular-level understanding of drusen begins with delicate tissue layers in the RPE-BrM-ChC complex and adjoining potential spaces (Fig. 1) . The anatomic definition of BrM 27 is five layers (from inner to outer), RPE-basal lamina (BL) and inner collagenous, elastic, and outer collagenous layers (inner collagenous layer [ICL], elastic layer [EL], outer collagenous layer [OCL] ). Pathology may be best understood with the Sarks-Gass concept of a three-layer BrM (ICLþELþOCL) that does not include the RPE and ChC basal laminas, thereby defining the subRPE-BL space between the RPE-BL and the ICL. Drusen are focal deposits located between the RPE-BL and the ICL of BrM, in the subRPE-BL space. BLinD is a thin layer of soft druse material, in the same compartment. This framework facilitates explaining the participation of basal laminar deposit (BLamD) in clinical AMD, the trajectory of type 1 (subRPE-BL) FIGURE 1. AMD by the layers. BrM consists of the ICL, EL, and OCL. Soft drusen and BLinD are two forms (lump and layer) of the same AMD-specific extracellular deposit. BLamD is a thickening of the RPE-BL. Basal mound is soft druse material within BLamD. Subretinal drusenoid deposit localizes to the subretinal space (between photoreceptors and RPE). RPE cells contain melanosomes, lipofuscin and melanolipofuscin, and mitochondria that provide signals for color fundus photography, fundus autofluorescence, and OCTs. Abbreviations from inner to outer: ONL, outer nuclear layer; ELM, external limiting membrane; IS, inner segments of photoreceptors; OS, outer segments of photoreceptors; R, rods; C, cones; L, lipofuscin; M, melanosome; ML, melanolipofuscin; Mt, mitochondria; Mu, Müller glia; circles, lipoprotein particles. neovascularization, the differing embryologic origins of RPE-BL versus ICLþELþOCL, and Mendelian disorders preferentially affecting the RPE-BL [28] [29] [30] versus structural elastin and collagen. 31, 32 By this definition, the Oil Spill in aging BrM 33 becomes the Oil Spill on BrM. Drusen are focal and can be recognized clinically. In contrast BLinD is thin and diffusely distributed, poorly visible in paraffin histology, and invisible clinically, leading to a common misperception that BrM thickens in AMD when in fact new layers are interposed (Fig. 1) .
IMAGING, EPIDEMIOLOGY, AND THE EXPANDING SPECTRUM OF DRUSEN
Drusen are the major intraocular risk factor for progression, and how they are detected clinically impacts theories of their formation and significance. 34 Drusen were linked to end-stages of geographic atrophy (GA) and neovascularization on a time course of years by Gass using color fundus photography (CFP) and fluorescein angiography, 35 as repeated in large samples. 36, 37 Major epidemiologic studies of European-derived populations since 1991 are based on standardized CFP-based grading systems. 38 Soft drusen are yellow-white elevations ranging from 30 lm to more than 1000 lm in diameter with an indistinct border due to sloping sides (Figs. 2C, 2F, 2I). increase risk in the aggregate and over the long term (15 years), in part by increasing risk for soft drusen. [40] [41] [42] East and South Asian populations have low prevalence of typical drusen but progress to neovascularization. 43, 44 Spectral-domain optical coherence tomography (OCT), commercialized in 2007, is an interferometry technique using low-coherence light to achieve depth-resolved, comprehensive, and noninvasive cross-sectional views of chorioretinal structure. Advancements, such as eye tracking and signal averaging, combine to make cross-sectional structural OCT the base modality for AMD clinical trials going forward. 45 By OCT, soft drusen are dome-shaped RPE elevations with homogenous and moderately reflective ''ground-glass'' interiors internal to BrM, which appears at the druse base as a fine reflective line. In small cohorts examined so far, soft drusen are the most common among macular druse types. 46 Internal structure in soft drusen visible on OCT signify risk for progression, [47] [48] [49] [50] [51] and approximately 10% of soft drusen may have subclinical (nonexudative) neovascularization. 52 A spectrum of RPE elevations now exists. [53] [54] [55] [56] [57] [58] [59] By the gold standard of histology of clinically documented cases (Fig. 2) , 40, [60] [61] [62] [63] hard and cuticular drusen are ultrastructurally similar, small, globular deposits 30 to 60 lm in diameter. Cuticular drusen are numerous in generally younger patients, exhibiting imaging signs of RPE attenuation at the apices. 64 A major limitation to current estimates of progression risk is the recent recognition of extracellular deposits in the subretinal space, between photoreceptors and RPE, first called reticular pseudodrusen 65 and recently, SDD. 66, 67 SDD is biologically distinct and not just drusen in the wrong place 34 (see the Subretinal Drusenoid Deposits: Extracellular, SpaceFilling, Distinct From Drusen section). SDD were in part misclassified as soft drusen or omitted altogether from five CFPbased grading systems [36] [37] [38] [68] [69] [70] [71] that underlie prevalence estimates, risk models, and genetic associations. Thus, risk attributed to soft drusen in some CFP-based grading systems is aggregate risk of soft drusen plus SDD. All literature must therefore be interpreted anew-do authors mean subretinal or subRPE? Did study eyes have SDD? Consequently, experimental studies must include highly polarized RPE cells for greatest AMD relevance (see the Model Systems for Mechanistic and Translational Drusen Research section).
INTRODUCTION TO CHOLESTEROL AND LIPOPROTEINS
Because ample multidisciplinary evidence supports lipoprotein particles as a major component of soft drusen, we introduce the chemistry and biology of cholesterol and lipoproteins (Fig.  3) ; comprehensive reviews are available. 72, 73 Cholesterol is a lipid with a hydrophobic four-ring system. A 3b-hydroxyl group binds long-chain fatty acids to form esters. We refer to Lipoproteins are spherical particles of uniform diameter with surfaceand-core morphology. They were originally described as vesicles in osmium postfixed specimens (A). RPE, (B, D) BLinD in an eye with geographic atrophy is a mixture of native and fused lipoprotein particles, with lipid pools, in the same plane, originally described as membranous debris in osmium postfixed specimens (B). (E) Lipoprotein particles isolated from BrM are large and spherical; negative stain, 144 scale bar: 50 nm. (F) BrM lipoprotein composition inferred from direct assay, 97, 144 druse composition, and RPE gene expression. 135, 358 Apo, apolipoproteins. ?, as-yet-unknown apolipoproteins. unesterified and esterified cholesterol (UC and EC), respectively. EC, accounting for approximately 70% of total cholesterol in humans, is used for storage and transport. UC is essential to all animal cells in roles of membrane integrity, fluidity, and permeability. Membrane UC is intercalated among phospholipids (PL) and concentrated in lipid rafts to influence many cellular activities, include gene transcription, nerve conduction, and synaptogenesis. Three physical forms-oily droplets, lamellar membranes, and monohydrate crystalsdiffer in the relative proportions of EC, UC, and PL. For transport through plasma and interstitial fluid, UC and EC form with apolipoproteins, PL, and triglycerides (TG) spherical multimolecular complexes called lipoproteins. Plasma lipoprotein classes identified by ultracentrifugation include (from large to small) chylomicrons (CM), very low-density (VLDL), lowdensity (LDL), and high-density (HDL) lipoproteins. Apolipoprotein B-100 (apoB-100) is the principal protein of LDL and is present with apoE in VLDL of hepatic origin, which is the parent particle of LDL. Apolipoprotein A-I (apoA-I) is the principal protein of plasma HDL. Brain HDL lipoproteins are rich in apoE. 74 Cross talk between plasma lipoproteins and complement components is under investigation. 73 Cells have many ways to efflux UC, and RPE may be capable of all, because some evidence currently exists for many. These include transfer to circulating HDL, 75 complexing with endogenously synthesized apolipoproteins, conversion to an oxysterol capable of passing through cellular membranes, 76 and release as microvesicles (budding of plasma membrane) or exosomes (trafficked from endosomes). 7 Conversely, lipoprotein particles and milk fat represent the only known ways by which cells release EC.
GENETICS AND GENE EXPRESSION STUDIES RELEVANT TO LIPIDS
AMD's major genetic associations are complement factor H (CFH) 78 and ARMS2, a gene with an uncertain function, now separated statistically from HTRA1, also on chromosome 10.
79
Among pathways, lipids are the most highly implicated after complement. 80 Candidate gene studies reported an association with AMD of single nucleotide polymorphisms (SNP) in APOE. 81, 82 Genome-wide association studies (GWAS) later also identified SNPs associated with advanced AMD in CETP, ABCA1, and LIPC, best known from plasma HDL homeostasis. 83, 84 The International Age-related Macular Degeneration Genomics Consortium found associations of these genes with AMD (n ¼ 16,144 cases and 17,832 controls) but with not elevated levels of plasma HDL 85 (see Refs. [86] [87] [88] . The Consortium dataset was probed via Mendelian randomization, 89 which showed that three variants of genes associated with plasma lipid levels (LIPC, 2; CETP, 1) reached genomelevel significance, placing AMD between cardiovascular disease and Alzheimer disease in the strength of lipid gene associations. SNPs in LIPC and ABCA1 are associated with intermediate and large drusen, and CFH, C3, C2, and ARMS2/HTRA1, large drusen. 90 A rare CFH variant is associated with abundant soft drusen, 91 and two CFH SNPs, with greater drusen area in central macula. 92 These studies and others 72, 93 suggest that lipid genes impact AMD risk significantly, yet independent of, or even reverse to, plasma lipoprotein profiles from cardiovascular disease, a paradox likely related to the existence of intraocular regulatory mechanisms. In normal human donor eyes, microarray 93 and comprehensive RNA-sequencing 94 analysis demonstrated that scores of genes controlling all aspects of cholesterol and lipoprotein homeostasis are expressed in both neurosensory retina and RPE. Immunolocalization using validated antibodies and polarized RPE (in vivo or high-fidelity culture, Refs. in 34) include APOE (photoreceptor outer segments, RPE, Müller cells, drusen, and SDD); ABCA1 (diffuse labeling of RPE cell bodies); CETP (photoreceptor outer segments and outer plexiform layer (OPL), with some labeling in the choroid); LIPC (all retinal neurons including photoreceptors and ganglion cells plus RPE, and not in Müller cells). Thus, theories of AMD pathogenesis based on genes well studied in liver, intestine, adipose tissue, and brain must also incorporate chorioretinal expression. 94 Human retina expresses two hallmark genes of hepatic and intestinal lipoprotein secretion, microsomal TG transfer protein (MTTP) and apoB (APOB) (for expert review see Ref. 95 ). Localization of both proteins in RPE and in retinal ganglion cells appears consistent with endoplasmic reticulum. 96 Secretion of full-length apoB-100 was demonstrated in rat- 97 and human-derived RPE cell lines 98 and in mouse RPE-choroid explants. 99 MTTP is a soluble heterodimer 100,101 that cotranslationally transfers lipid to apoB to ensure correct folding. 102, 103 Cells expressing apoB without MTTP cannot secrete lipoproteins. [104] [105] [106] [107] ApoB production is regulated via co-and posttranslational degradation by the ubiquitin-proteasome system, which is in turn regulated by lipid availability. 108 ApoB's classic function is delivering exogenous and endogenous TG, cholesterol, and lipophilic vitamins throughout the body as part of VLDL/LDL and chylomicrons. ApoB is also expressed in kidney, placenta, and heart, 109, 110 apparently to regulate TG content and forestall lipotoxicity. 111 In mice, absence of apoB is lethal in utero, and reduced apoB causes neural tube defects. 112, 113 Lack of functional MTTP and apoB results in abetalipoproteinemia (ABL, OMIM 200100) and hypobetalipoproteinemia (HBL, OMIM 615558), rare Mendelian disorders that include a pigmentary retinopathy and ataxic neuropathy. Attributed to impaired delivery of lipophilic vitamins, ABL/HBL are partly alleviated by long-term dietary supplementation. 114 Intraocular apoB and MTTP expression indicates that ABL/HBL are intrinsic degenerations and that lipoprotein assembly and secretion are required for retinal health and good vision. It also means abundant research on hepatic and intestinal lipoproteins are relevant to AMD.
SOFT DRUSEN, BLIND: LIFELONG PHYSIOLOGY, UNCOVERED BY AGING
In the 19th century Donders, 115 Wedl, 116 and Müller 117 discovered drusen; Wedl 116 described them as lipid globules. Long-standing theories for druse formation 117 are transformation of the overlying RPE and deposition of materials onto BrM. The latter is now accepted. 118 S.H. and J.P. Sarks, two ophthalmologists in Australia, together and in collaboration with pathologist M.C. Killingsworth, contributed foundational AMD pathology, including the heterogeneity of drusen within a heterogeneously presenting disease. 23, 40, 60, 65, [119] [120] [121] [122] Studies using panoramic electron microscopy of affected macular tissue from clinically documented eyes of S.H. Sarks' patients 40, 60, [119] [120] [121] 123, 124 definitively localized drusen in the subRPE-BL space, distinct from the overlying RPE-BL/BLamD and underlying ICL, and proved that clinical druse phenotypes differed in ultrastructure and thus in composition. 60 Soft drusen are dome-shaped with sloping sides 125 and filled with 'membranous debris' 60 (Figs. 2, 4 ), implying lipids, and considered by the Sarks to set the disease course. Soft drusen and BLinD are two physical forms (lump and layer, respectively), often continuous, 126 of the same material; BLinD was also called ''diffuse drusen'' by paraffin histology. 127 When soft drusen/BLinD are processed for conventional thin-section electron microscopy using osmium postfixation, biomechanical fragility 23, 128, 129 and partial extraction of lipid combine to produce curvilinear elements resembling coiled membranes (Figs. 4C, 4D) . Thus, the principal soft druse component was initially called membranous debris, 120, 123 influencing mechanistic hypotheses and development of model systems exhibiting cellular membrane release. 130, 131 Also, descriptions of aging BrM using conventional osmium postfixed tissue mentioned vesicles (i.e., membranous coils with aqueous interiors). 132, 133 Lipid-preserving histochemical and ultrastructural techniques united ''vesicles'' and ''membranous debris'' as manifestations of lipoprotein particles at different levels of preservation and disintegrity. Evidence for lipoprotein involvement is best for pre-BLinD (Fig. 3C ) and hard drusen, where electron-dense spherical particles are visible, and more than 40% of druse volume is Folch-extractable lipid. 134 Soft drusen/ BLinD are biomechanically fragile (called ''localized detachments of BLamD'') 127 so evidence for their composition rests on consistent ultrastructural and histochemical results across studies. Soft drusen/BLinD exhibit polygonal regions of homogeneously and moderately electron-dense material (Fig.  4) , originally called ''hard drusen breaking up.'' When prepared by sterol-specific filipin histochemistry, these shapes are EC-rich lakes. 135, 136 Similar processes occur in the lipid-rich cores of atherosclerotic plaques, where plasma LDL insudates 137, 138 and binds to extracellular matrix, followed by particle surface degradation, fusion, and pooling of core lipids to create UC-rich liposomes 139, 140 ; these processes can be mimicked in vitro by physically disrupting LDL. 141 A natural history of aging BrM (17-92 years) using osmium tannic acid post-fixation showed that ''vesicles'' were solid, spherical particles approximately 80 nm in diameter. Further, quick-freeze deep-etch analysis of BrM (27-86 years; Fig.  3C ) 17, 142 revealed that particles had a surface-and-core morphology consistent with lipoproteins. 143, 144 Lipoprotein particles also appear in multivesicular bodies in BrM, 17, [144] [145] [146] and in lines crossing BLamD. 126, 127, 147, 148 Both studies demonstrated three to four rows of densely packed lipoproteins in the subRPE-BL space, logically the direct precursors of BLinD. This formation, first called Lipid Wall, represents preBLinD (Fig. 3C) . 143, 144 The nondescript fluid phase surrounding particles contain proteins and other components not discernible at these magnifications. We proposed the name ''lipoprotein-derived debris'' 149 for masses of modified lipoproteins in soft drusen/BLinD (Figs. 3D, 4C, 4D ). This debris also appears in basal BLamD (basal mounds) 121, 123, 150, 151 and rarely, within large vacuoles in RPE. 123, 126, 152 Similar material said to occupy the subretinal space 66, 123 is really SDD (see the Subretinal Drusenoid Deposits: Extracellular, Space-Filling, Distinct From Drusen section).
A lipophilic barrier in aged BrM blocking normal, choroiddirected fluid efflux from the RPE was postulated by Bird and Marshall 153 to explain RPE detachments in older adults. A seminal study by Pauleikhoff et al. 16 demonstrated that oil red O binding lipids localized exclusively to BrM of healthy human eyes. This staining was abundant in adults 61 years and older, variably present in midlife adults, and absent in young adults. Direct assay confirmed the age-related increase (although not the initially reported composition). 154, 155 Marshall employed BrM explants to explore transport across this tissue. [156] [157] [158] Later analysis showed excellent correlation of an age-related increase in resistivity (inverse of hydraulic conductance) with content of hydrophobic EC. 159 Specific histochemistry and analytic biochemistry combine with gene expression (see the Genetics and Gene Expression Studies Relevant to Lipids section) to support the concept of EC-and linoleate-rich, apoB, apoE-containing, large lipoprotein particles secreted by RPE (Figs. 3E, 3F) . The oil red O-binding material is EC, verified by multiple direct assays. 17, 97, 144, 160 EC accumulates markedly in BrM, in 7-fold higher quantities in macula than periphery. 17, 18 EC localizes exclusively to BrM whereas UC and PL, also present, additionally localize to nearby cellular membranes. 161 Particles 60 to 80 nm in diameter and with flotation properties and spherical shapes indicating neutral lipid cores are isolable from healthy human BrM. 97, 144 In the same fractions are also apolipoproteins B, A-I, and E. BrM lipoproteins are highly EC-enriched relative to TG, 17, 97, 144, 160 unlike hepatic VLDL, of similar diameter. Thus, BrM lipoproteins are large like VLDL and EC-rich like atherogenic LDL. In contrast, the neurosensory retina contains little EC. 17, 160 Lipoproteins are assembled from multiple lipid sources, and fatty acid profiling of EC and other lipid classes in BrM lipoproteins and extracts allowed inferences about the source of this component. Docosahexaenoate (22:n6) is distinctively high in PL of outer segment membranes 162 and neural tissue in general. Yet, high-performance liquid chromatography in two laboratories showed that all lipid classes in BrM are overwhelmingly dominated by the fatty acid linoleate (18:2, most abundant in plasma) with little docosahexaenoate. 97, 160 This result suggests that RPE recycles docosahexaenoate back to photoreceptors efficiently, as postulated, 163 and that plasma lipoproteins are the major fatty acid sources to BrM lipids. On the basis of fatty acid composition alone, it is not possible to distinguish BrM lipoproteins from those of plasma origin, in transit to RPE from choriocapillaris. However, BrM lipoprotein composition and gene expression support a local source, because enrichment with EC over TG differs sharply from plasma VLDL, and intracellular gene and protein data (see the Genetics and Gene Expression Studies Relevant to Lipids section) indicate RPE capacity for lipoprotein assembly and secretion.
A long-standing hypothesis 164 states that debris in aging BrM represents outer segment membranes phagocytosed and processed by RPE. 165 Outer segment UC content is notably low 93, 166, 167 but could be concentrated in bulk phagocytosis by RPE.
150 Figure 5 expands this model by postulating that the fatty acids in this material come largely from diet. BrM lipid deposition (steps 1-2, Fig. 5 ) is proposed as a recycling system in which plasma lipoproteins delivering dietary essentials are stripped of cargo destined for photoreceptors. Unneeded fatty acids and UC are repackaged with outer segment UC for secretion to BrM and eventual choroidal clearance. One appeal of this model is the specificity for BrM, unlike models involving by-products of other lipids. 168, 169 Soft drusen/BLinD form (steps 3-4, Fig. 5 ) when egress is blocked through aging BrM/ ChC, either due to abnormal amounts or types of BrM proteins, loss/dysfunction of ChC, loss of VEGF sustenance to ChC, or all. Aged BrM and subsequent soft drusen/BLinD could act as a transport barrier to large molecular complexes, 170 a source of peroxidizable proinflammatory lipids, 171, 172 and part of an increased diffusion distance impeding oxygen exchange. 173 
THE CALCIFIC END-STAGE OF SOFT DRUSEN AND DIFFERENTIATION FROM AMYLOID b
One end-stage of soft drusen is calcification, inferred from glistening fundus appearance 35 and in tissues, refractility, 62, 123 von Kossa staining, 128, 174, 175 and microanalysis. 176 Concentric shells within spherules impart the glistening appearance and a punctate reflectivity on OCT. 175 Spherules less than 1-lm diameter 177 show strong hydroxyapatite signal via microprobe synchrotron x-ray fluorescence and specific dyes, 178, 179 and they may enclose other druse components and promote deposit expansion. 179 Nonreflective multilobular nodules calcific (5-100 lm) within drusen are associated with reduced autofluorescence signal of overlying RPE. 49, 177 Hydroxyapatite is also abundant in subRPE deposits created by well-differentiated cultured RPE, 151 emphasizing the importance of basolaterally directed physiologic mineral regulation.
An alternate interpretation stems from the finding of colocalized and spherically distributed activation fragments of complement C3 with amyloid b peptide, a major constituent of Alzheimer disease neuritic plaques 180 in some drusen of some AMD eyes, 181 with staining correlated to overall drusen load per eye. 182 Light and electron microscopy showed concentric shells, 129,182 which were not labeled by antibodies to other amyloids. 183, 184 Many proteins bind to hydroxyapatite, 185 which is used in chromatography, raising the possibility that amyloid binding to spherules is nonspecific. Amyloid b peptide was recently found in inner retina of Alzheimer patients, signifying a separate neurodegeneration, distant from drusen. 186 
OTHER COMPONENTS OF SOFT DRUSEN
Understanding druse composition is considered an important route to discern pathways perturbed in AMD 187 (Supplementary  Table S1 ). ApoE was an early, consistent, and abundant component. 81, 135, 187, 188 Proteomics and immunohistochemistry also revealed vitronectin, complement components, clusterin, ATP synthase subunit beta, scavenger receptor B2, and retinol dehydrogenase. 134, [189] [190] [191] Oxidatively modified proteins including tissue metalloproteinase inhibitor 3 and vitronectin, and carboxyethyl pyrrole protein adducts also 191 supporting oxidative damage as important in AMD progression. 192 Many proteins, minerals such as zinc, and carbohydrates can be confidently placed in macular drusen that confer progression risk (Supplementary Table S1 ). However, it is unclear if these signals are specific to macula, a question of biologic importance. 4 Data comparing macular and peripheral drusen in the same eyes are sparse. 129, 193 The macula is 3% of total retinal area, 194 requiring specific measures for its analysis. Many studies assayed peripheral drusen, 134, 182 combined macular and peripheral drusen, 191 or did not specify regional source. 189 The apparent synergy of immunohistochemistry with genetic associations implicating complement was largely based on labeling that cannot be definitively placed in the macula. Neither membrane attack complex (terminal element of the complement cascade) 195 nor CD59 196 localized to macular soft drusen. Experimental studies suggest that BrM lipoprotein binding can be modulated by plasma CFH factor H, 197 and genetics implicate a role for CFH in soft drusen biogenesis (see the Genetics and Gene Expression Studies Relevant to Lipids section). Continued investigation is warranted.
RPE LIPOFUSCIN -DISTINCT FROM DRUSEN
RPE lipofuscin comprises abundant and long-lasting intracellular inclusion bodies, related to lysosomes, which are rich in bisretinoids (vitamin A derivatives). 198 Appearing in humans in childhood and increasing throughout adulthood, RPE lipofuscin is the principal signal source of fundus autofluorescence imaging. Lipofuscin has been proposed as a source of intermediates in the pathway to age-related glycation products in drusen. 199, 200 Evidence included in vitro studies 201 exposing cells to a lipofuscin fluorophore recently found to be less abundant in macula than in periphery. [202] [203] [204] [205] [206] [207] Histopathology of human AMD eyes indicate that lipofuscin is present in RPE 40, 60, 121, 123 and rarely in drusen. 129 Further evidence that lipofuscin is not a major source of druse components includes different topographies of lipofuscin (high in perifovea 208, 209 ) and soft drusen (high in central macula) and different emission spectra of fluorophores in lipofuscin versus soft drusen. 210 Because lipofuscin-attributable autofluorescence is a superb reporter of RPE metabolism that can be combined with OCT for subcellular-level insight in vivo, 211 the biology and role in AMD pathophysiology of RPE lipofuscin remains a research priority.
BLAMD -DISTINCT FROM DRUSEN, IMPORTANT IN DRUSE BIOGENESIS
BLamD is a distinct deposit meriting its own study (Fig. 1) . Continuous subfoveal BLamD is considered diagnostic for AMD, and continuous BLamD in the presence of BLinD is an early AMD threshold. 119, 212 BLamD's role besides association with drusen can now be explored in clinical OCT. If RPE is present, BLamD is shadowed and appears hyporeflective. 213 If RPE is absent, BLamD is a moderately reflective line across the atrophic macula. 214, 215 In many older healthy eyes BLamD forms small patches (~5-lm wide) between the basolateral RPE plasma membrane and the RPE-BL. Early (palisade) BLamD is discontinuous, thin, and fibrous. In AMD, continuous BLamD is 15-lm thick or more. 121, 150, 216 Late BLamD is thick, multilayered, and scalloped on the inner aspect. 123, 126, 147, 214 BLamD ultrastructure resembles basement membrane, containing laminin, fibronectin, type IV, and type VI collagen with 120-nm periodicity, [217] [218] [219] [220] as well as vitronectin, matrix metalloproteinase (MMP), metalloproteinase inhibitor 3 (TIMP-3), C3, and C5b-9. 216 suggesting it is a nonspecific RPE stress response with a specific role in AMD. BLamD and BLinD are often jointly named ''basal deposits.'' This imprecise term (to which this author added 148 ) comes from low resolution paraffin and cryosection histology and is unwarranted if epoxy-resin histology or transmission electron microscopy is available. The commendable goal of ''determining the origin and pathogenesis of BLamD and BLinD as a route to preventive measures'' 127 is best served by high-resolution visualization techniques and precise terminology.
SUBRETINAL DRUSENOID DEPOSITS: EXTRACELLULAR, SPACE-FILLING, DISTINCT FROM DRUSEN
As reviewed, 34 ''drusen seen in blue light'' reported in 1990 224 were called various names depending on detection technology and patient population, 225 finally settling on reticular pseudodrusen (viewed en face) 65 and SDD (viewed cross-sectionally). 66, 67 In 1988 Sarks et al. 123 described by electron microscopy ''focal collections of membranous debris'' 123 in the subretinal space (see the Soft Drusen, BLinD: Lifelong Physiology, Uncovered by Aging section). 65 In a donor eye, Rudolf et al. 66 described regularly spaced deposits, distinct from photoreceptors and RPE. Definitive histology of clinical cases 122, 226 established the presence of extracellular deposits. The association of SDD with atrophy, 227 intraretinal neovascularization, 228 and photoreceptor degeneration 229, 230 indicates a place for SDD in the AMD spectrum. 1 Beyond location, SDD differs from soft drusen/BLinD (Table 1) in lipid, protein, and mineral content, specificity for AMD, and association with neovascular subtypes. 34 A histologic survey of AMD donor eyes 225 showing that SDD was thickest in the perifovea, and that soft drusen/BLinD was thickest under the fovea, leading to a novel suggestion that deposits reflect differential physiology of rod and cone photoreceptors, respectively. Hypothesized driving pathways include lipid transport via lipoproteins (Fig.  5) and/or interphotoreceptor retinoid binding protein. 34 A comprehensive understanding of SDD molecular composition is urgently needed.
PROOF-OF-CONCEPT VIA DRUSEN-IN-A-DISH CULTURE SYSTEMS
The BrM lipoproteins that make up soft drusen are thus postulated as dual-source, with fatty acids coming from uptake of plasma lipoproteins and cholesterol coming from outer segments as well (Fig. 5) . If diet is an important driver of 232 and culture well inserts that allow independent monitoring of apical and basal chambers of polarized cells, essential for parsing druse-and SDD-relevant pathways. In a proof-of-principle study by Johnson et al., 146 cultured fetal human RPE on 100-lm thick porous supports in a standard medium without retinal supplementation produced particulate deposition of apoE-immunoreactive material within the insert (replicated in Ref. 151) .
Using a 10-lm thick polyester membrane that restricted access to the basal compartment to pores crossing the insert, Pilgrim et al. 151 found that beginning at 8-weeks polarized and highly differentiated primary porcine RPE lay down extensive deposits on the insert surface. Deposits were approximately 2-lm thick, extracellular, electron-dense, continuous, and sometime focal, with similar material filling the insert pores. Deposits exhibited histochemical and spectroscopic signatures of soft drusen, including lipid, apoE, and hydroxyapatite. Because cells were polygonal, had good transepithelial resistance, and expressed RPE-specific genes, including MTTP, cells appeared functional. Thus, deposits formed, because egress through the insert was blocked as the pores filled. These data strongly suggest that dietary input is required for druse initiation. Outer segments are not required, although they clearly shape deposit composition in vivo, nor were exogenous stressors. Learning what aspects of culture medium are essential will require selective depletion experiments.
Similarly, Galloway et al. 233 showed that induced pluripotent stem cells (iPS) from patients with inherited retinopathies (see the BLamD -Distinct From Drusen, Important in Druse Biogenesis section) also generate electron-dense deposits between the RPE-BL and culture dish inserts. Deposit was generally sparse and discontinuous and varied according to genotype. Layers of collagen IV and apoE immunoreactivity resembled the RPE-BL and subRPE-BL space in vivo, respectively. Contrary to previous findings, 146 exposure to human serum was not required to initiate deposits but did enrich them with C5b-9 immunoreactivity. Deposit sparseness relative to Pilgrim et al. 151 may be due to withdrawal of fetal bovine serum and/or use of iPS cells at passage 3. The authors concluded that RPE dysfunction leads to deposits in these iPS cells that express mutant genes. 233 However, deposits can be made by wild-type, differentiated porcine RPE. 151 Culture systems are valuable when functional RPE can be studied in isolation and can demonstrate the minimum requirements for deposit. They offer limited mechanistic insights beyond that, in the absence of choroid and retina. In vivo, the ''insert'' to which RPE-BL attaches is ICL of BrM. Data suggest that aged BrM/ChC acts as a physical barrier to retain constitutively secreted material that accumulates (as it does in vivo) under the RPE. 142 Neither cell culture studies nor other approaches have addressed whether BrM protein composition, BrM molecular sieving properties, inefficient translocation by aging ChC endothelium, or other factors initiate the binding of lipid in situ. [234] [235] [236] Atherosclerosis research may be a source of ideas. 237, 238 HOW SOFT DRUSEN LEAD TO ATROPHY AMD natural history is now visualizable at the cellular level with optimized structural eye-tracked OCT imaging. 239 A pathway from soft drusen to subRPE neovascularization, includes gradients of VEGF secretion by stressed RPE, macrophage activity in breaching BrM, invading capillaries that remove or replace friable deposits, and damage to surrounding cells by peroxidized lipids. 192, 221, 240 Recent data now also strongly implicate drusen as a causative factor in GA, further stimulating interest in targeting drusen to prevent or delay atrophy.
Clinicopathologic correlation, 124 epidemiology, 41, 241, 242 and clinical observation 243 show that hyperpigmentation is the largest intraocular risk factor for progression after drusen abundance. In OCT, intraretinal hyperreflective foci found overlying drusen [244] [245] [246] [247] and appearing frequently in photoreceptor layers 47, 248 are correlated with hyperpigmentation on CFP 248, 249 and are now attributed to anteriorly migrated RPE. 250 Reflective foci seen by either in vivo or ex vivo OCT could be directly linked to intraretinal RPE by histology [251] [252] [253] [254] [255] [256] and distinguished from cells with lipid droplets (presumed microglia or macrophages) in neovascular AMD. 252, 255 A highresolution histology survey of RPE morphology suggested two main pathways of RPE fate. 239 One pathway, apparently apoptotic, comprised the shedding of RPE organelles into underlying BLamD. A second pathway comprised rounding and sloughing of cells into the subretinal space, followed by anterior migration into the neurosensory retina, in coordination with Müller cells and photoreceptors at the external limiting membrane.
Drusen are dynamic, coalescing and disappearing in a manner suggestive of regulated processes. 60, [257] [258] [259] [260] Over 5 to 7 years, 20% to 34% spontaneously disappear. [261] [262] [263] Others disappear after retinal detachment. 91 Drusenoid pigment epithelial detachment (PED; i.e., drusen with >350 lm base diameter) is a defined route to atrophy. 123, 264 A PED lifecycle was determined by measuring deposit volume in OCT scans for periods up to 6.6 years. 265 Deposits grew slowly and collapsed quickly, with a legacy of complete RPE and outer retinal atrophy (Fig. 6 ). Before collapse, the RPE layer thickened at the druse apex, hyperreflective foci appeared vertically above in the retina, and the RPE-BL disintegrated. 254 A similar lifecycle was demonstrated independently for more than 6000 RPE elevations of varying sizes. 266 In some eyes, RPE death/ migration leaves a raised line of reflective persistent BLamD across the atrophic area. 215 These spatiotemporal characteristics together with cell culture studies (see the Proof-of-Concept Via Drusen-in-a-Dish Culture Systems section) clarify how RPE cells die over drusen. If a druse is growing, the RPE is functional enough to secrete druse components, which then back up against the BrM-ChC complex due to slowed clearance. 151 When the druse gets large enough, RPE cells on the apex either migrate or die. Then the druse collapses, because druse component production is discontinued, and clearing processes catch up. It has been thought that as drusen collapse, the RPE dies, but the contrary is true. Further, because drusenoid PED are the largest deposits on a continuum leading to GA, we can judiciously extrapolate to drusen-associated atrophy overall. 267 Interestingly, other clinical studies support this overall model, including drusen over choroidal nevi that compress ChC 59 and diminished ChC flow signal under drusen by OCT angiography. 268 Anterior migration of RPE suggests attractants from the retina, repellents in the druse, or both. Oxygen tension is reduced by 30% to 50% at druse apices, depending on height.
173,269 RPE atop drusen are maximally distant from the ChC and may migrate to seek oxygen from retinal capillaries. In intraretinal neovascularization (retinal angiomatous proliferation), ectopic RPE cells positive for VEGF immunoreactivity are found immediately adjacent to capillaries. 255, 270, 271 Further, druse volume is a strong predictor of which individual deposits
proceed to atrophy. 272 Data can support a model of RPE cell death related to distance from the ChC, in concert with local lipotoxicity, 172 driven by hypoxia, micronutrient deficiency, and bioenergetic failure, with drusen the common underlying mechanism.
CONTINUING TO LEARN FROM ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Atherosclerotic cardiovascular disease has been a rich source of molecules, mechanisms, techniques, and inspiration for approaching the biology of soft drusen and new treatments and preventions. Arguably, the several biologic pathways for AMD risk outlined by meta-analyses of GWAS 80, 273 align along an atherosclerotic progression.
72 Table 2 keeps this comparison in perspective by showing that despite many similarities at the level of the vessel wall, from calcific end-stages to extracellular matrix regulation to lipoprotein sources of cholesterol, the top-level biologic risk factors of AMD and cardiovascular disease (e.g., plasma LDL and apoE4 genotype) are dissociated. The evidence that lipid deposition in aging BrM is dictated by needs of outer retinal cells and not an ocular manifestation of systemic perifibrous lipid in human connective tissues and atherosclerosis is compelling. Nevertheless, the commonality of lipoproteininstigated vascular disease suggests that the many antidyslipidemic agents developed for cardiovascular disease may be intelligently probed for their utility in AMD.
THERAPEUTIC APPROACHES TO SOFT DRUSEN
Our hypotheses motivate the pharmacologic targeting of soft drusen components and antecedent processes to prevent downstream sequelae, a strategy similar to that used for stroke: target vessel walls, so neurons and supporting cells will benefit. We elaborated the Oil Spill strategies (Fig. 7) 33,72 : detoxifying or removing drusen (''Skimmers and Dispersants''), retarding drusen formation by preventing RPE lipoprotein outflow (''Top Kill''), and preventing drusen formation by modulating dietary input (''Bottom Kill'').
Statins are widely used inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting enzyme for cholesterol synthesis, that reduce plasma LDL by upregulating LDL receptors throughout the body, especially the liver. Because statins also directly reduce apoB secretion, 274 they are dualaction Top Kill and Bottom Kill, because RPE and RPE-derived cells expresses LDL receptors, 275 secrete apoB, and respond differentially to various statins. 98 Clinical evidence regarding statin efficacy for AMD has been equivocal. [276] [277] [278] Retrospective and population-based studies included patients at varying AMD severity levels, used statins of varying lipophilicity, and predated concepts of intraocular cholesterol and lipoprotein homeostasis. Several authors have advocated revisiting statins. 98, 279, 280 In a double-masked randomized placebo-controlled proofof-concept trial by Guymer and associates, 279 114 normolipemic AMD patients received either simvastatin 40 mg/day or placebo. Patients with bilateral intermediate AMD receiving simvastatin experienced a significant 2-fold decrease in the risk of progression, with no effect seen in unilateral intermediate AMD (advanced AMD in the fellow eye). Further, a single-arm, two-center trial of 80 mg/day atorvastatin reported by Vavvas and associates 281 showed that over 1 year, 10 of 23 patients exhibited marked reduction of large drusen, lack of progression to atrophy and neovascularization, and quiet RPE over druse domes. Three patients dropped out due to side-effects not uncommon at this dose. Although this study lacked quantification of druse volume and a comparison group to account for the natural history of druse dynamism, results were singular and corroborated the previously seen lack of progression. 279 A ''Skimmers and Dispersants'' approach is exemplified by a recent preclinical study of a lipid scavenger. 282 Apolipoprotein (apo) A-I mimetics are short (18 amino acids) synthetic amphipathic helical peptides that emulate the antiatherogenic properties of apoA-I (243 amino acids). 283, 284 Amphipathicity allows peptides to sequester lipids and travel through an aqueous environment. Peptide 4F has four phenylalanine residues on the nonpolar face of the helix. [283] [284] [285] [286] [287] [288] [289] It is antiinflammatory, avidly binding oxidized phospholipids and fatty acid hydroperoxides 290 and reducing large-artery atherosclerosis in animal models. 283, [291] [292] [293] In phase II trials for cardiovascular disease, systemic 4F was tolerated, 294, 295 but not advanced, due to uneven absorption after oral administration. 4F's small size and the commonality of lipoprotein-instigated vascular disease in atherosclerosis and AMD made it an excellent candidate for targeting drusen and/or druse precursors. A popular model of atherosclerosis, ApoE À/À mice also exhibit BrM disintegrity, thickening, and EC accumulation at 10 to 11 months. 282 One eye was injected with 4F or a scrambled peptide (0.6, 1.2, 2.4 lg), and the fellow eye served as a control. Transmission electron microscopy and perfringolysin-green fluorescent protein histochemistry showed at all doses that BrM ultrastructure improved and EC was reduced. 296 Animals receiving 4F tagged with a fluorescent tracer exhibited fluorescence at 1 day postinjection in BrM, remaining for at least 14 days, while replenished from neurosensory retina. Many questions remain, including effects on plasma inflammatory markers, precise lipids removed, safety profile, and effects on retinal function. 17, 143 Despite limitations, this study demonstrated a tolerated and effective pharmacologic reduction of BrM lipids from mice. 126, 129 Because soft drusen are extracellular and loosely packed, 126, 129 surface-active agents like 4F offer advantages. Unlike targeting extracellular drusen, other lipid-based approaches involve intracellular RPE lipid. For example, the offloading of cellular cholesterol to circulating HDL via LXR agonists 297 may reduce substrate available for apoB lipidation and druse biogenesis. Another approach is to stimulating RPE uptake of lipids, presumably to clear drusen (e.g., via the CD36 scavenger receptor). 298 It is instructive to recall that among agents modulating VLDL for cardiovascular disease, the lipid content of source cells was a less fruitful target than impacting the vessel wall through plasma lipid-lowering. Indeed, inhibitors of hepatic microsomal triglyceride transfer protein (MTTP) and acyl cholesterol acyltransferase-1 caused steatosis (fatty liver). 108, [299] [300] [301] [302] Investigators should thus check for RPE lipoidal degeneration, a steatosis-like intracellular accumulation of lipid droplets associated with depressed electroretinograms. [303] [304] [305] [306] A major roadblock to clinical trials of drugs targeting drusen is nonavailability of approved and appropriate endpoints, although candidates exist. Visual acuity can remain good until late AMD. Rod-mediated dark adaptation and low-luminance visual acuity are sensitive to early disease stages but take time to administer. [307] [308] [309] The only imaging endpoint currently approved by regulatory authorities is slowed expansion of GA viewed with fundus autofluorescence, a bar which several agents failed to meet. [310] [311] [312] [313] It is possible that GA is too late for intervention, because photoreceptor degeneration and gliosis are already severe. 123, [314] [315] [316] [317] [318] A earlier-stage surrogate endpoint is druse volume, 261 in the causal pathway to progression and readily calculable from OCT scans. 319 Another potential surrogate is hyperreflective foci over drusen (migrating RPE 254 ), a risk factor for atrophy 47, 51, 320 that can be quantified.
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MODEL SYSTEMS FOR MECHANISTIC AND TRANSLATIONAL DRUSEN RESEARCH Monkeys: Drusen Without Progression
Monkeys in closed colonies have strong matrilines that vary in the degree of AMD pathology. 321 They share with humans AMD susceptibility genes 322 and plasma hyperlipidemias. 323 To date, monkeys have not exhibited neovascularization, GA, BLamD, SDD, migratory RPE, or drusen with internal structure visible on OCT, 306 all typical for human AMD; this possibly reflects a controlled environment and diet. Yet some monkeys appear to have soft drusen and requisite Oil Spill biology. Drusen with ''membranous debris'' and lipoproteinlike particles in BrM were demonstrated by electron microscopy. 303 BrM exhibits both oil red O and filipin staining for EC. 305 A large study (n ¼ 60 eyes, 2-to 26-years old) showed an age-related increase in immunoreactivity for 7-ketocholesterol, an oxidation product of UC, 172 that was selective for RPE-choroid. Like humans, monkey drusen contain apoE 324 and carbohydrates, 325 and BrM has entrapment sites (i.e., upward swellings of the ICL). Unlike humans, monkeys have cellular processes evaginated from RPE. 40, 326 Mouse Models Capture Some Pathways Well
Mice are experimentally advantageous yet exhibit only some AMD-relevant biology. Relative to humans and nonhuman primates, mice differ in the following ways: they are nocturnal; lack an all-cone fovea, foveal pit, centrifugal displacement of photoreceptor terminals, and long Henle fibers; have small cones and densely packed outer segments; naturally lack xanthophyll pigment; exhibit subretinal microglia in aging and in retinal degenerations; have a uniform distribution of bisretinoid A2E in RPE; have panretinal multinucleate RPE (versus in Ref. Nevertheless, components of AMD can be studied to great effect in genetically engineered mice. Several models exhibit BLamD, sometimes containing lipid, 223, [328] [329] [330] [331] [332] suggesting that mice have apolipoprotein pathways but normally lack a retentive matrix. Other mouse strains have EC in BrM, 99, 296, 333 activated RPE, 334, 335 spontaneous intraretinal neovascularization, 336, 337 and xanthophyll accumulation. 338 Because AMD-risk genes like APOE are expressed in several outer retinal cell types, technologies for cell-specific knockouts will be especially informative. 339, 340 It is agreed that mice lack drusen (hard or soft). 197, 341 Several studies claimed drusen in mice [342] [343] [344] [345] [346] but did not meet the Sarks standard of ultrastructurally confirmed focal, extracellular, subRPE-BL material, correlated to fundus appearance. Regularly spaced microglia appear in the subretinal space of several aging mouse strains, [347] [348] [349] and correlate to neither human drusen nor SDD. 226, 350 Precision in specifying layer and ultrastructural findings in animal models and benchmarking against human pathology will accelerate progress on AMD.
Cell Culture Systems are Standardizing
Several RPE culture systems produce druse-relevant deposits, 146, 151, 233 with one recreating a continuous deposit.
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Confluent and polygonal with sharp vertices, healthy RPE in vivo maintains the physiologic blood-retina barrier and exercises distinct roles visà vis photoreceptors and the choroid. Due to AMD deposits of differing composition in subretinal and subRPE-BL compartments, polarity is more essential than ever for RPE culture systems. Many protocols exist for high-fidelity native and engineered RPE in culture, emphasizing properties of the intact layer, particularly high transepithelial resistance ( ‡250 MX). 77, 146, 231, 232, [351] [352] [353] [354] [355] Of current interest, cell-based therapies are raising expectations for all RPE culture systems. 356 Studies using nonconfluent cells, cells with low transepithelial resistance, and high-passage cell lines, such as human-derived ARPE-19, should be interpreted cautiously. Ideally cultured RPE should be characterized for polarity, barrier function, cytoskeletal precision, and expression of RPE-specific genes.
FINAL THOUGHTS
Soft drusen are a very prominent intraocular risk factor that are seen routinely in vivo. Yet the true impact of soft drusen on AMD progression will be better understood when all the layers in Figure 1 can be followed clinically and their contribution to risk assessed. In less than decade thanks to OCT, SDD went from invisible to a major contributor to retinal dysfunction. Now the participation of BLamD is also becoming known. We anticipate a day when BLinD is visible clinically and its risk assessed along with drusen. In 2007 the Sarks et al. 121 staged eyes by the presence of 'membranous debris'. Arguably some of AMD's infamous heterogeneity is because this specific pathology cannot be directly followed in the clinic. Thus, presentations currently attributed to individual variability may be consequences of invisible BLinD (or other invisible deposits). For example, Asian populations prone to neovascularization without many drusen may have BLinD that escapes detection. Fortunately, imaging technologies with promise of revealing BLinD are emerging. 210, 357 There is still much to learn about the biology of soft drusen, in the clinic and in the laboratory. Nevertheless, current knowledge can motivate targeting these deposits and contributory biologic processes, to delay or avoid AMD's sight-robbing late stages.
Limitations to this analysis are sparse experimental confirmation of hypotheses largely generated from human tissues and patients. Our hypotheses, while speculative, bring together many evidence lines and do not exclude other major extant hypotheses for AMD biology and may in fact occur in parallel.
